RxDoctor Payments Data

Nirupa Mohandas, MD

Rheumatology · Jackson, MSNPI 1467533190

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Amgen accounts for 71.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $410 and has fallen 65.0% since, to $144 in 2025. That places this record below the midpoint for rheumatology clinicians in MS, where the typical reported total is $8,210.

$1,146in general payments, 2019–2025

Across 41 payments — averaging $27.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$822
  • Lilly USA, LLC$106
  • Stemline Therapeutics Inc.$71
  • GSK$35
  • Boehringer Ingelheim$26
  • AbbVie$25
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$1,146100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,146 in reported general payments places this provider in the 30th percentile of 44 rheumatology providers in Mississippi.

See all rheumatology providers in Mississippi

Medicare billing

Part B allowed, 2024
$3,121
Medicare patients
20
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab124$813,018
Xeljanz XrTofacitinib Citrate21$115,435
EnbrelEtanercept13$91,103
Actemra ActpenTocilizumab14$33,037
Hydroxychloroquine Sulfate98$5,934
MethotrexateMethotrexate Sodium185$5,771
Leflunomide23$1,557
Colchicine13$910
Diclofenac Sodium25$448
Prednisone81$365
Gabapentin54$217
Allopurinol16$157
Folic Acid62$98
Cyclobenzaprine Hcl21$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$822$91,10313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 44 rheumatology providers in Mississippi.

Other rheumatology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →